Comprehensive multi-omics analysis of breast cancer reveals distinct long-term prognostic subtypes
-
Published:2024-06-13
Issue:1
Volume:13
Page:
-
ISSN:2157-9024
-
Container-title:Oncogenesis
-
language:en
-
Short-container-title:Oncogenesis
Author:
Sharma AbhibhavORCID, Debik JuliaORCID, Naume Bjørn, Ohnstad Hege Oma, , Sahlber Kristine Kleivi, Borgen Elin, Børresen-Dale Anne-Lise, Engebråten Olav, Fritzman Britt, Garred Øystein, Geisler Jürgen, Geitvik Gry Aarum, Hofvind Solveig, Kristensen Vessela N, Kåresen Rolf, Langerød Anita, Lingjærde Ole Christian, Mælandsmo Gunhild Mari, Russnes Hege G, Sauer Torill, Skjerven Helle Kristine, Schlichting Ellen, Sørlie Therese, Bathen Tone F., Giskeødegård Guro F.
Abstract
AbstractBreast cancer (BC) is a leading cause of cancer-related death worldwide. The diverse nature and heterogeneous biology of BC pose challenges for survival prediction, as patients with similar diagnoses often respond differently to treatment. Clinically relevant BC intrinsic subtypes have been established through gene expression profiling and are implemented in the clinic. While these intrinsic subtypes show a significant association with clinical outcomes, their long-term survival prediction beyond 5 years often deviates from expected clinical outcomes. This study aimed to identify naturally occurring long-term prognostic subgroups of BC based on an integrated multi-omics analysis. This study incorporates a clinical cohort of 335 untreated BC patients from the Oslo2 study with long-term follow-up (>12 years). Multi-Omics Factor Analysis (MOFA+) was employed to integrate transcriptomic, proteomic, and metabolomic data obtained from the tumor tissues. Our analysis revealed three prominent multi-omics clusters of BC patients with significantly different long-term prognoses (p = 0.005). The multi-omics clusters were validated in two independent large cohorts, METABRIC and TCGA. Importantly, a lack of prognostic association to long-term follow-up above 12 years in the previously established intrinsic subtypes was shown for these cohorts. Through a systems-biology approach, we identified varying enrichment levels of cell-cycle and immune-related pathways among the prognostic clusters. Integrated multi-omics analysis of BC revealed three distinct clusters with unique clinical and biological characteristics. Notably, these multi-omics clusters displayed robust associations with long-term survival, outperforming the established intrinsic subtypes.
Publisher
Springer Science and Business Media LLC
Reference59 articles.
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209–49. 2. Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750–69. 3. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52. 4. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001;98:10869–74. 5. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol. 2011;5:5–23.
|
|